In Vitro: κ-Car- Curcumin (Cur) (0-500 μg/mL; 24-72 hours) effectively involves in cancer cell growth inhibition at lower concentrations of 40 μg/mL. The cytotoxicity of the Cur loaded κ-Car has a significantly high apoptotic activity in selected lung cancer cells of A549. κ-Carrageenan (1-60 μg/mL; 0.5-24?hours) enhances LPS-induced IL-8 secretion in HT-29 cells.
In Vivo: κ-Carrageenan can be used in animal modeling to establish rat and mouse paw edema models.
κ-Carrageenan (1.7-41.7 mg/kg; p.o. for 1 week prior to C. freundii DBS100 treatment) can synergistically activate LPS-induced inflammatory through the Bcl10-NF-κB pathway, as indicated by its aggravation of C. freundii DBS100-induced colitis in mice. κ-Carrageenan enhances the C. freundii DBS100-dependent induction of TLR4 and NF-κB in the intestinal mucosa of infected mice. κ-Carrageenan aggravates the TNBS-induced intestinal inflammation, and such an effect could be associated with the oxidative stress and activation of TLR4-NF-κB and MAPK/ERK1/2 pathway